- Home
- MESO vs SVM Comparison
MESO vs SVM Comparison
Compare MESO & SVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MESO
- SVM
- Stock Information
- Founded
- MESO 2004
- SVM N/A
- Country
- MESO Australia
- SVM Canada
- Employees
- MESO N/A
- SVM N/A
- Industry
- MESO Biotechnology: Biological Products (No Diagnostic Substances)
- SVM Precious Metals
- Sector
- MESO Health Care
- SVM Basic Materials
- Exchange
- MESO Nasdaq
- SVM Nasdaq
- Market Cap
- MESO 1.3B
- SVM 1.4B
- IPO Year
- MESO N/A
- SVM N/A
- Fundamental
- Price
- MESO $18.18
- SVM $7.08
- Analyst Decision
- MESO Buy
- SVM Strong Buy
- Analyst Count
- MESO 2
- SVM 1
- Target Price
- MESO $24.00
- SVM $6.75
- AVG Volume (30 Days)
- MESO 319.1K
- SVM 7.4M
- Earning Date
- MESO 08-28-2025
- SVM 11-06-2025
- Dividend Yield
- MESO N/A
- SVM 0.35%
- EPS Growth
- MESO N/A
- SVM N/A
- EPS
- MESO N/A
- SVM 0.25
- Revenue
- MESO $17,198,000.00
- SVM $308,064,000.00
- Revenue This Year
- MESO $288.50
- SVM $10.42
- Revenue Next Year
- MESO $167.17
- SVM $39.88
- P/E Ratio
- MESO N/A
- SVM $28.26
- Revenue Growth
- MESO 191.39
- SVM 35.50
- 52 Week Low
- MESO $7.09
- SVM $2.87
- 52 Week High
- MESO $22.00
- SVM $7.50
- Technical
- Relative Strength Index (RSI)
- MESO 58.45
- SVM 67.61
- Support Level
- MESO $17.10
- SVM $6.58
- Resistance Level
- MESO $20.18
- SVM $7.50
- Average True Range (ATR)
- MESO 0.56
- SVM 0.36
- MACD
- MESO 0.17
- SVM 0.02
- Stochastic Oscillator
- MESO 55.52
- SVM 75.00
About MESO Mesoblast Limited
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.
About SVM Silvercorp Metals Inc.
Silvercorp Metals Inc is a mineral exploration company, engaged in the acquisition, exploration, development, and mining of mineral properties. The company's producing mines are located in China, and exploration and development projects are located in China and Ecuador. Its project portfolio comprises the El Domo copper-gold and the Condor gold project in Ecuador. In addition, it operates several silver-lead-zinc mines at the Ying Mining District in Henan Province, China, and the GC silver-lead-zinc mine in Guangdong Province, China. A majority of the company's revenue is generated through the sale of silver concentrates. Its reportable operating segments are the Ying Mining District and GC Mine in China, which derive maximum revenue, and the El Domo and Condor projects in Ecuador.